Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BMRA 
Biomerica Inc (BMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: BMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -85.28% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.02M USD | Price to earnings Ratio - | 1Y Target Price 13 |
Price to earnings Ratio - | 1Y Target Price 13 | ||
Volume (30-day avg) - | Beta 0.33 | 52 Weeks Range 1.93 - 8.80 | Updated Date 06/29/2025 |
52 Weeks Range 1.93 - 8.80 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -85.42% | Operating Margin (TTM) -108.13% |
Management Effectiveness
Return on Assets (TTM) -35.99% | Return on Equity (TTM) -72.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5377116 | Price to Sales(TTM) 1.41 |
Enterprise Value 5377116 | Price to Sales(TTM) 1.41 | ||
Enterprise Value to Revenue 0.95 | Enterprise Value to EBITDA -5.42 | Shares Outstanding 2545760 | Shares Floating 2384045 |
Shares Outstanding 2545760 | Shares Floating 2384045 | ||
Percent Insiders 10.13 | Percent Institutions 5.8 |
Upturn AI SWOT
Biomerica Inc
Company Overview
History and Background
Biomerica Inc. was founded in 1971. Initially focused on gastroenterology diagnostics, it has evolved to develop and commercialize medical products used primarily for the early detection of medical conditions and diseases. The company expanded its offerings through internal development and acquisitions.
Core Business Areas
- Gastroenterology Diagnostics: Offers diagnostic tests and products for gastrointestinal diseases and disorders, including Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth (SIBO), and Helicobacter pylori (H. pylori) detection.
- Allergy Diagnostics: Develops and markets tests for food allergies and sensitivities.
- Point-of-Care Diagnostics: Focuses on developing and commercializing rapid diagnostic tests for various medical conditions, including infectious diseases and cardiac markers.
Leadership and Structure
Zackary Irani is the Chairman, President, and CEO. The company operates with a functional organizational structure, with departments for research and development, manufacturing, sales and marketing, and finance and administration.
Top Products and Market Share
Key Offerings
- InFoods IBS Diagnostic: A diagnostic test for Irritable Bowel Syndrome (IBS). Limited market share data available; competitors include Commonwealth Diagnostics International. Revenue is growing. Competitors include CDx and Mayo Clinic Labs.
- EZ Detect colorectal disease screening test: An in-home fecal occult blood test for colorectal cancer screening. Limited market share data; competes with Exact Sciences' Cologuard and other FOBT tests. Competitors include Exact Sciences and Epigenomics.
- Hp-Detect: A rapid test for the detection of H. pylori infection. Competitors include QuidelOrtho and Roche.
Market Dynamics
Industry Overview
The medical diagnostics industry is characterized by technological innovation, increasing demand for point-of-care testing, and regulatory oversight. Key trends include personalized medicine and the shift towards preventive care.
Positioning
Biomerica Inc. is positioned as a developer and marketer of niche diagnostic tests, focusing on areas with unmet needs and opportunities for early detection.
Total Addressable Market (TAM)
The global diagnostics market is projected to reach hundreds of billions of dollars. Biomerica occupies a small segment and focuses on niche markets. The InFoods IBS diagnostic test targets a significant portion of the IBS market, estimated in the billions globally.
Upturn SWOT Analysis
Strengths
- Niche product portfolio
- Proprietary technologies
- Established distribution network
- Strong focus on R&D
Weaknesses
- Limited financial resources
- Reliance on key products
- Small market capitalization
- Concentration of revenue in a few products
Opportunities
- Expansion into new geographic markets
- Development of new diagnostic tests
- Strategic partnerships and acquisitions
- Increasing demand for point-of-care diagnostics
Threats
- Competition from larger diagnostic companies
- Regulatory changes
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- EXAS
- DGX
- HOLX
Competitive Landscape
Biomerica faces intense competition from larger, more established diagnostic companies. Its competitive advantages include niche products and proprietary technologies. Disadvantages include limited financial resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Growth has been uneven, with periods of rapid expansion followed by stagnation or decline.
Future Projections: Future growth depends on successful commercialization of new products and expansion into new markets. Analyst estimates are not consistently available, and are extremely volatile.
Recent Initiatives: Recent initiatives include the expansion of the InFoods IBS diagnostic and development of new point-of-care tests.
Summary
Biomerica is a small diagnostic company with niche products but inconsistent financial performance. Its strengths lie in its focus on unmet medical needs and its established distribution network. The company needs to address its limited financial resources and competition from larger players. Growth depends on successful product commercialization and market expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q), press releases, analyst reports, market research reports.
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomerica Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2005-01-03 | CEO & Director Mr. Zackary S. Irani | ||
Sector Healthcare | Industry Medical Devices | Full time employees 64 | Website https://www.biomerica.com |
Full time employees 64 | Website https://www.biomerica.com | ||
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.